Dr. Yaqiong Guo |microbiome |best researcher award

Dr. Yaqiong Guo, Institute of Biotechnology and Health, Beijing Academy of Science and Technology, China

Dr. Yaqiong Guo 🧬 is an Assistant Researcher at the Institute of Biotechnology and Health, Beijing Academy of Science and Technology 🏥. Specializing in microbial genomics and gut microbiome research 🦠, her work explores how microbiota influences diseases like diabetes and lung cancer 💉🫁. With a Ph.D. in Genetics from the Chinese Academy of Sciences 🎓 and multiple research projects under her belt, she brings cutting-edge bioinformatics and metagenomics expertise to human health studies 💻🔬. Dr. Guo has authored key publications in top journals 📚 and actively leads national-level scientific projects contributing to precision medicine in China 🇨🇳.

Professional Profile:

orcid

✅ Summary of Suitability

Dr. Yaqiong Guo brings a strong scientific foundation, advanced research experience, and a focused interest in microbiome-related disease mechanisms. Her ability to lead projects, secure funding, and publish in prestigious journals makes her highly suitable for collaborative academic, clinical, or biotech environments. With a strategic focus on human health and precision medicine, she is well-positioned to contribute meaningfully to multidisciplinary research and innovation.

🔹 Education & Experience 

🎓 Education

• 🧬 Ph.D. in Genetics, Institute of Microbiology, Chinese Academy of Sciences (2017–2023)

• 💻 B.Sc. in Bioinformatics, Hebei University (2013–2017)

💼 Professional Experience

• 🧪 Assistant Researcher, Institute of Biotechnology and Health, BAST (2023–Present)

• 🔬 Ph.D. Candidate, Institute of Microbiology, CAS (2017–2023)

• 🔹 Professional Development 

  Dr. Guo’s professional journey combines robust academic training and hands-on research in cutting-edge genomics 🧪💻. As principal investigator and collaborator on projects supported by NSFC, BAST, and other major institutions 🇨🇳, she has led efforts in unraveling microbial gene functions in chronic diseases 🩸. Her technical proficiency spans microbial genomics, bioinformatics, and statistical data analysis 📊. Her work contributes to developing new diagnostic and therapeutic tools in precision medicine 🧬🎯. As an author in Nature Communications and other journals 📚, she continues to elevate microbial science at the intersection of human health and biotechnology 🌐🔍.

• 🔹 Research Focus Category 

  Dr. Guo’s research centers on microbial genomics and host-microbiome interactions 🧫🔬. She investigates how gut microbial genes and metabolism contribute to complex diseases like diabetes mellitus, diabetic kidney disease, and lung cancer 🩺🫁. With a metagenomic and systems biology approach, she analyzes large-scale microbiome data to uncover biomarkers and disease mechanisms 🔍📈. Her interest in antibiotic resistance, microbial traceability, and precision interventions demonstrates her commitment to translational health science and public safety 💊⚠️. Her research plays a critical role in designing microbiome-based diagnostics and therapies 🧠🧬, aligning closely with global health and biomedical priorities 🌍.

• 🔹 Awards & Honors 

  🏆 Research Grants & Project Roles

  • 🎯 PI, Gut Microbial Genes & Diabetic Kidney Disease – BAST Reform Project (¥135,000, 2024)

  • 🔬 Co-PI, NSFC Antibiotic Resistance Mechanisms (¥3,500,000, 2020–2024)

  • 🧠 Co-PI, Jinan Precision Microbial Data Methods (¥1,850,000, 2022–2023)

  • 💉 Co-PI, Target Screening for Type 2 Diabetes & DKK – Fiscal Project (¥945,426, 2023)

  • 🦠 Co-PI, Pathogenic Gene Analysis – National Key R&D (¥1,400,000, 2018–2021)

  📚 High-impact Publications

  • Published in Nature Communications, Microorganisms, Scientia Sinica Vitae, Acta Microbiologica Sinica

Publication Top Notes:

1. Dynamic Changes in Antibodies and Proteome in Breast Milk of Mothers Infected with Wild-Type SARS-CoV-2 and Omicron: A Longitudinal Study

• Authors: Yaqiong Guo, Cheng Li, Minjie Tan, Yuexiao Chen, Shuai Zhu, Cheng Zhi, Jing Zhu

• Journal: Nutrients

• Publication Date: April 21, 2025

Summary: This longitudinal study investigates the dynamic changes in antibodies and proteomic profiles in breast milk from mothers infected with either the wild-type SARS-CoV-2 or the Omicron variant. The research aims to understand how maternal infection influences the immune components of breast milk over time, potentially affecting neonatal immunity. The study provides insights into the temporal patterns of antibody presence and proteomic alterations, contributing to the understanding of maternal-infant immunity in the context of COVID-19.

2. An Expanded Database and Analytical Toolkit for Identifying Bacterial Virulence Factors and Their Associations with Chronic Diseases

• Authors: Wanting Dong, Xinyue Fan, Yaqiong Guo, Siyi Wang, Shulei Jia, Na Lv, Tao Yuan, Yuanlong Pan, Yong Xue, Xi Chen, et al.

• Journal: Nature Communications

• Publication Date: September 15, 2024

Summary: This study presents the development of VFDB 2.0, an expanded virulence factor gene (VFG) database comprising 62,332 nonredundant orthologues and alleles. Accompanying this database is the MetaVF toolkit, designed for precise identification of pathobiont-carried VFGs at the species level. Analysis of 5,452 commensal isolates from healthy individuals revealed that only 11 of 301 species harbored these factors. Further examination of gut microbiomes from nine chronic disease cohorts uncovered both common and disease-specific VFG features. Notably, in type 2 diabetes patients, long-read sequencing confirmed that shared VFG features were carried by pathobiont strains of Escherichia coli and Klebsiella pneumoniae. These findings underscore the importance of identifying and understanding VFGs in microbiome-associated diseases.PubMed+1PMC+1

3. Association Studies on Gut and Lung Microbiomes in Patients with Lung Adenocarcinoma

• Authors: Yaqiong Guo, Wenjie Yuan, Na Lyu, Yuanlong Pan, Xiaoqing Cao, Yuxuan Wang, Yi Han, Baoli Zhu

• Journal: Microorganisms

• Publication Date: February 21, 2023

Summary: This study explores the associations between gut and lung microbiomes in patients with lung adenocarcinoma (LADC). By analyzing paired fecal and bronchoalveolar lavage fluid samples from 42 LADC patients and 64 healthy controls using 16S rRNA gene amplicon and shotgun metagenome sequencing, the researchers observed reduced alpha-diversity and altered beta-diversity in the gut microbiome of LADC patients. Increased abundances of Flavonifractor, Eggerthella, and Clostridium were noted, with Flavonifractor plautii linked to advanced-stage LADC and higher metastasis rates. Haemophilus parainfluenzae emerged as the most frequently shared taxon in the lung and gut microbiota of LADC patients. Additionally, gut microbiome functional pathways involving leucine, propanoate, and fatty acids were associated with LADC progression. The study highlights the potential role of the gut-lung axis in LADC development and progression.PMC

 

🧾 Conclusion

Dr. Yaqiong Guo stands out as a rising scientific leader who is advancing microbiome research in medically meaningful and globally relevant directions. Her combination of technical depth, project leadership, and translational outcomes makes her not only suitable but highly deserving of a Best Researcher Award.